Physician profile
Paula King
NPI 1740781491
$2,928.69
in general payments reported to CMS, 2019-2025
14 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.45 · 2022: $224 · 2023: $780 · 2024: $803 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $603.12 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $532.60 | 2022-2025 | Dysport |
| Janssen Biotech, INC. | $420.34 | 2022-2025 | Tremfya |
| Abbvie INC. | $343.72 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $271.41 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $262.02 | 2023-2025 | Absorica Ld, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $225.35 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.81 | 2023-2025 | Spevigo |
| Leo Pharma INC. | $55.06 | 2023-2024 | Adbry |
| Ucb, INC. | $51.23 | 2024-2025 | Bimzelx |
| Incyte Corporation | $22.47 | 2022 | |
| Abbott Laboratories | $20.45 | 2021 | |
| Biofrontera INC. | $19.04 | 2022 | |
| Verrica Pharmaceuticals INC. | $17.07 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.